Feasibility Study of Metformin Therapy in ADPKD

University of Colorado, Denver56 enrolled

Overview

This study is being done to determine if treatment with metformin, a drug widely used for the treatment of diabetes type 2, is safe and well tolerated by individuals with Autosomal Dominant Polycystic Kidney Disease (ADPKD) who are not diabetic and who have slightly decreased kidney function. The study will also evaluate the effects of metformin on kidney growth and kidney function.

Patients with ADPKD are still in need for a well-tolerated treatment that can be used long-term to prevent cyst growth and kidney function decline. Metformin has a long track record of a low risk-to-benefit profile in patients with diabetes or at risk for diabetes. Metformin inhibits two key processes responsible for the growth of polycystic kidneys, i.e. fluid secretion and cell proliferation, as shown in cell cultures and animal models of ADPKD. Experiments in animal models of chronic kidney disease demonstrate that metformin administration prevents kidney fibrosis and preserves kidney function. Diabetic patients who are treated with metformin appear to develop less kidney failure and live longer than patients who are treated with other anti-diabetic medications. Therefore this drug is promising for people with ADPKD, with the potential to slow cyst enlargement and preserve kidney function.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Polycystic Kidney, Autosomal Dominant

Interventions

MetforminDRUG

Monitoring of safety and tolerability

PlaceboDRUG

Monitoring of safety and tolerability

Eligibility

Sex: ALLMin age: 30 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Autosomal Dominant Polycystic Kidney Disease and * An estimated glomerular filtration (GFR) rate of 50-80 ml/min/1.73 m2; * Subject is able to sign an Informed Consent Exclusion Criteria: * Diabetes mellitus, * Active infection, * Congestive heart failure, * Liver disease, * Alcohol or substance dependence, * Cigarette smoking within the last 12 months; * Females who are pregnant or breast feeding, or * Are unwilling to use contraception; * Are unable to undergo magnetic resonance imaging, or * Have a contraindication to the use of metformin

Locations (1)

University of Colorado Denver, Anschutz Medical Campus

Aurora, Colorado, United States

Outcomes

Primary Outcomes

Safety and Tolerability of Metformin

Percentage of participants who at the end of 12 months are still prescribed the full randomized dose of metformin or placebo, and the percentage of participants who are prescribed at least 50% of the randomized dose

Time frame: 12 months

Secondary Outcomes

Change in Total Kidney Volume

Total kidney volume will be measured by MRI (magnetic resonance imaging) at baseline and at 12 months. Percentage change from baseline in height-adjusted total kidney volume is reported.

Time frame: 12 months

Change in Kidney Function

Estimated glomerular filtration rate (eGFR) will be calculated from serum creatinine measurements at baseline and after 3, 6, 9 and 12 months. Change from baseline at 12 months is reported.

Time frame: 12 months

Rate of Serious Adverse Events (SAE)

Serious adverse events occurring from the time of signing informed consent until the end of the study will be monitored in both treatment arms

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.